share_log

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144:拟议出售证券
美股sec公告 ·  07/09 16:27
Moomoo AI 已提取核心信息
Recursion Pharmaceuticals, Inc. Director Blake Borgeson is set to sell 11,447 Class A shares of the company on 07/09/2024, as per the latest SEC filing. These shares, originally acquired on 09/01/2016 as founder's shares in compensation for Borgeson's role, are valued at an aggregate market value of $83,734.73. This planned sale follows a series of transactions over the past three months, where a total of 77,289 shares were sold for gross proceeds of approximately $692,134.77. The upcoming sale represents a continuation of Borgeson's regular divestment of shares in the company.
Recursion Pharmaceuticals, Inc. Director Blake Borgeson is set to sell 11,447 Class A shares of the company on 07/09/2024, as per the latest SEC filing. These shares, originally acquired on 09/01/2016 as founder's shares in compensation for Borgeson's role, are valued at an aggregate market value of $83,734.73. This planned sale follows a series of transactions over the past three months, where a total of 77,289 shares were sold for gross proceeds of approximately $692,134.77. The upcoming sale represents a continuation of Borgeson's regular divestment of shares in the company.
Recursion Pharmaceuticals,Inc.董事Blake Borgeson打算于07/09/2024卖出11,447股A类公司股份,根据最新的SEC备案。这些股份最初是在2016年9月1日作为创始人股份作为Borgeson角色的补偿获得的,总市值为$83,734.73。此次计划的销售是继过去三个月的一系列交易之后,共出售77,289股,总收入约为$692,134.77。即将到来的销售代表了Borgeson定期剥离公司股份的持续。
Recursion Pharmaceuticals,Inc.董事Blake Borgeson打算于07/09/2024卖出11,447股A类公司股份,根据最新的SEC备案。这些股份最初是在2016年9月1日作为创始人股份作为Borgeson角色的补偿获得的,总市值为$83,734.73。此次计划的销售是继过去三个月的一系列交易之后,共出售77,289股,总收入约为$692,134.77。即将到来的销售代表了Borgeson定期剥离公司股份的持续。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息